BioNTech SE Sponsored ADR $BNTX Stock Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management cut its BioNTech stake by 70.4% in the third quarter, selling 28,124 shares and retaining 11,843 shares valued at approximately $1.16 million.
• BioNTech’s CEO Ugur Sahin sold 72,000 shares worth about $7 million under a pre-arranged Rule 10b5-1 plan; insiders sold roughly $79.2 million of stock during the quarter.
• The company reported a quarterly loss of $2.53 per share and revenue of $122.3 million, missing estimates and declining 59.5% year over year. Analysts’ consensus remains “Moderate Buy,” with a $125.80 price target.

Robeco Institutional Asset Management B.V. reduced its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 70.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,843 shares of the company's stock after selling 28,124 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in BioNTech were worth $1,164,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth about $39,000. Farther Finance Advisors LLC grew its stake in BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company's stock valued at $48,000 after buying an additional 118 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock valued at $177,000 after buying an additional 1,423 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in BioNTech by 232.8% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company's stock valued at $188,000 after acquiring an additional 1,341 shares during the period. Finally, Quantum Portfolio Management LLC bought a new position in BioNTech in the 1st quarter valued at about $203,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioNTech

In other news, CEO Ugur Sahin sold 72,000 shares of BioNTech stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00. Following the completion of the sale, the chief executive officer directly owned 108,209 shares in the company, valued at approximately $10,521,161.07. The trade was a 39.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock worth $79,246,837 over the last quarter. 19.20% of the stock is currently owned by company insiders.

BioNTech Price Performance

NASDAQ:BNTX opened at $86.86 on Tuesday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The firm's 50-day simple moving average is $98.36 and its 200 day simple moving average is $97.44. The firm has a market cap of $21.97 billion, a price-to-earnings ratio of -11.09 and a beta of 1.25.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period in the prior year, the firm earned ($1.60) EPS. The business's revenue for the quarter was down 59.5% on a year-over-year basis. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.62 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. BMO Capital Markets downgraded shares of BioNTech from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. UBS Group reaffirmed a "buy" rating on shares of BioNTech in a research report on Wednesday, September 16th. Morgan Stanley lowered their target price on BioNTech from $115.00 to $114.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of BioNTech in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $125.80.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company's research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech's oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.